Promising Results for Detection of Microscopic Tumors Presented at 46th American Society of Hematology Meeting by Children's Hos
December 07 2004 - 9:00AM
PR Newswire (US)
Promising Results for Detection of Microscopic Tumors Presented at
46th American Society of Hematology Meeting by Children's Hospital
Boston An Increase in Angiogenic Regulatory Proteins in Blood
Platelets, Potentially Useful for Early Cancer Diagnosis, Can be
Detected Using SELDI-TOF-MS FREMONT, Calif., Dec. 7
/PRNewswire-FirstCall/ -- Scientists at the Children's Hospital
Boston working in collaboration with scientists from Ciphergen
Biosystems, Inc. (NASDAQ:CIPH), presented results today at the
American Society for Hematology 46th Annual Meeting in San Diego
suggesting proteomic analysis of circulating platelets can
potentially be useful for early cancer diagnosis. Principal authors
of the study, Dr. Giannoula Klement and Dr. Judah Folkman, state in
their abstract: "...using SELDI-TOF-mass spectrometry of platelet
extracts, we have found that this novel property of platelets
detects human cancers of a microscopic size undetectable by any
presently available diagnostic method. The platelet angiogenic
profile is more inclusive than a single biomarker because it can
detect a wide range of tumor types and tumor sizes. Relative
changes in the platelet angiogenic profile permit the tracking of a
tumor throughout its development, beginning from an early in situ
cancer." Platelets from mice bearing microscopic, clinically
undetectable tumors of human liposarcoma were compared to
tumor-free mice using Ciphergen's SELDI-TOF-MS based ProteinChip(R)
Biomarker System and Arrays. The proteomic profiling of platelets
at different stages of tumor growth, resulted in the finding of
increased amounts of angiogenic regulatory proteins such as VEGF,
bFGF, PDGF, PF4, endostatin and tumstatin, in platelets, but not in
plasma. The study goes on to confirm that these regulatory proteins
can be taken up by platelets in a selective and quantifiable manner
even when a source as small as 100 microliter Matrigel pellet is
implanted subcutaneously. The researchers were able to demonstrate
that this represents a selective sequestration process and not a
simple association with the platelet surface. This finding of
selective uptake of angiogenic regulators by platelets without a
corresponding increase of these proteins in plasma points to the
potential applicability of platelet-derived angiogenic biomarkers
for early cancer diagnosis. "We are delighted to see that our SELDI
ProteinChip technology has enabled the discovery and quantifiable
assay of biomarkers, which potentially may be used for early
diagnosis of cancer allowing for earlier treatment," stated William
E. Rich, President and CEO of Ciphergen Biosystems. About Ciphergen
Ciphergen develops, manufactures and markets a family of
ProteinChip(R) Systems and services for clinical, research and
process proteomics applications. ProteinChip Systems and Biomarker
Discovery Center(R) collaborative services enable protein
discovery, profiling, characterization and assay development to
provide researchers with predictive analysis capabilities and a
better understanding of biological functions at the protein level.
ProteinChip Systems are enabling tools in the emerging field of
protein-based biology research, known as proteomics. Proteomics
provides a direct approach to understanding the role of proteins in
the biology of disease, monitoring disease progression and
evaluating the therapeutic effects and side effects of drugs.
Ciphergen believes proteomics will be a major focus of biological
research by enhancing the understanding of gene function and the
molecular basis of disease. Additional information about Ciphergen
can be found at http://www.ciphergen.com/. Safe Harbor Statement
Note Regarding Forward-Looking Statements: For purposes of the
Private Securities Litigation Reform Act of 1995 (the "Act"),
Ciphergen disclaims any intent or obligation to update these
forward-looking statements, and claims the protection of the Safe
Harbor for forward-looking statements contained in the Act.
Examples of such forward-looking statements include statements
regarding the use of ProteinChip technology to perform proteomic
analyses of blood platelets that potentially can diagnose cancer at
an early stage and track a tumor's development, and future growth
in the field of proteomics. Actual results may differ materially
from those projected in such forward-looking statements due to
various factors, including the ProteinChip technology's ability to
validate and/or develop these proteomic analyses of blood platelets
as diagnostic assays, and the continued emergence of proteomics as
a major focus of biological research and drug discovery. Investors
should consult Ciphergen's filings with the Securities and Exchange
Commission, including its Form 10-Q dated November 9, 2004, for
further information regarding these and the other risks of the
Company's business. NOTE: Ciphergen, ProteinChip and Biomarker
Discovery Center are registered trademarks of Ciphergen Biosystems,
Inc. DATASOURCE: Ciphergen Biosystems, Inc. CONTACT: investor
relations, Sue Carruthers of Ciphergen Biosystems, Inc.,
+1-510-505-2297 Web site: http://www.ciphergen.com/
Copyright
Ciphergen Biosystems (NASDAQ:CIPH)
Historical Stock Chart
From May 2024 to Jun 2024
Ciphergen Biosystems (NASDAQ:CIPH)
Historical Stock Chart
From Jun 2023 to Jun 2024